Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

 
• By Sten Stovall

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.

Samples
AZ And Merck Seek Lynparza Use Across Multiple Tumor Settings • Source: Shutterstock

More from New Products

More from Scrip